Hasbro, DENTSPLY SIRONA, Prothena Corporation among premarket losers' pack

Nov. 14, 2022 8:32 AM ETXRAY, HAS, BCLI, VS, SLS, PRTA, MOR, TRMR, HOOK, STOK, STSA, OTLY, SNALBy: Meghavi Singh, SA News Editor

Satsuma Pharmaceuticals (STSA) -83% after reporting topline results from the STS101 SUMMIT Phase 3 efficacy trial.
MorphoSys (MOR) -30% as Licensing Partner Roche faces another setback in Alzheimer's as gantenerumab fails phase 3 trials.
Tremor International (TRMR) -27% on Q3 earnings release.
SELLAS Life Sciences (SLS) -14% on Q3 earnings release.
Versus Systems (VS) -13%.
Oatly (OTLY) -12% on Q3 earnings release.
Stoke Therapeutics (STOK) -11% on Q3 earnings release.
Snail (SNAL) -11%.
DENTSPLY SIRONA (XRAY) -9% on Q3 earnings release.
Brainstorm Cell Therapeutics (BCLI) -8% on Q3 earnings release.
Prothena Corporation (PRTA) -7%.
Hasbro (HAS) -6% after double downgrade from BofA to bearish rating.
HOOKIPA Pharma (HOOK) -5% on Q3 earnings release.